Abstract

This conceptual analysis discloses, as defensive prior art (CC BY 4.0), a capacity-safety-cost decision framework for delivering oxygen-carrying support where compatible allogeneic blood is unavailable (trauma, remote/military, mass-casualty, rare blood phenotypes). No experimental data are generated; all scores are relative, literature-informed estimates. An earlier version proposed oral perfluorocarbon (PFC) as a systemic oxygen supplement; that claim is quantitatively implausible and is withdrawn here. The framework instead compares three oxygen-carrier modalities: (A) enteral PFC oxygenation, for which oxygenated perfluorochemical delivered to the gut lumen has been shown to ameliorate respiratory failure in mammals (Okabe et al., Med 2021); (B) intravenous PFC emulsion (perflubron/Oxygent), a transient peri-operative oxygen bridge limited by low physically-dissolved capacity (Riess 2001); and (C) a haemoglobin-based oxygen carrier (HBOC-201/Hemopure), offering near-blood capacity but carrying a cardiovascular-safety signal (increased myocardial infarction and death in a meta-analysis of 13 trials; Natanson et al., JAMA 2008). Scoring capacity, safety, non-invasiveness, and regulatory maturity with documented cost estimates and hard clinical gates, no single modality is universally ideal; each is admissible in a distinct setting: A for pre-hospital/field use without intravenous access, B for elective transfusion-sparing surgery, and C as a monitored last resort when no compatible blood exists. The disclosure keeps these accessible, non-proprietary options in the public domain so that no party can patent and monopolize them. This is a prior-art disclosure, not deployment, regulatory, or clinical guidance.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS